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JNK2 is required for efficient T-cell activation and apoptosis but
not for normal lymphocyte development
Kanaga Sabapathy*, Yinling Hu†, Tuula Kallunki†‡, Martin Schreiber*,
Jean-Pierre David*, Wolfram Jochum*, Erwin F. Wagner* and Michael Karin†
Background: The Jun N-terminal kinase (JNK) signaling pathway has been
implicated in cell proliferation and apoptosis, but its function seems to depend
on the cell type and inducing signal. In T cells, JNK has been implicated in both
antigen-induced activation and apoptosis.
Results: We generated mice lacking the JNK2 isozymes. The mutant mice were
healthy and fertile but defective in peripheral T-cell activation induced by
antibody to the CD3 component of the T-cell receptor (TCR) complex —
proliferation and production of interleukin-2 (IL-2), IL-4 and interferon-γ (IFN-γ)
were reduced. The proliferation defect was restored by exogenous IL-2. B-cell
activation was normal in the absence of JNK2. Activation-induced peripheral
T-cell apoptosis was comparable between mutant and wild-type mice, but
immature (CD4+CD8+) thymocytes lacking JNK2 were resistant to apoptosis
induced by administration of anti-CD3 antibody in vivo. The lack of JNK2 also
resulted in partial resistance of thymocytes to anti-CD3 antibody in vitro, but
had little or no effect on apoptosis induced by anti-Fas antibody,
dexamethasone or ultraviolet-C (UVC) radiation. 
Conclusions: JNK2 is essential for efficient activation of peripheral T cells but not
B cells. Peripheral T-cell activation is probably required indirectly for induction of
thymocyte apoptosis resulting from administration of anti-CD3 antibody in vivo.
JNK2 functions in a cell-type-specific and stimulus-dependent manner, being
required for apoptosis of immature thymocytes induced by anti-CD3 antibody but
not for apoptosis induced by anti-Fas antibody, UVC or dexamethasone. JNK2 is
not required for activation-induced cell death of mature T cells.
Background
Mitogenic, inflammatory and stress signals are transduced
by evolutionarily conserved pathways that modulate
expression of genes controlling cell proliferation, survival
and death. These signals activate members of the mitogen
activated protein (MAP) kinase family, which can translo-
cate to the nucleus to phosphorylate various transcription
factors [1,2]. Several MAP kinase subgroups differing in
their response and substrate specificities, including the
extracellular-signal-regulated kinases (ERKs), the Jun 
N-terminal kinases (JNKs) and the p38s, have been
described. All MAP kinases are regulated upstream by
MAP kinase kinases and MAP kinase kinase kinases.
Unlike the ERK pathway, which is activated most effec-
tively by growth factors [1], the JNK and p38 pathways [3]
are stimulated primarily by proinflammatory and stress
stimuli [4–7], although they also respond to mitogens
[8,9]. Activated JNKs phosphorylate the transcription
factors c-Jun and ATF2, which participate in activation
and formation of the AP-1 complex [6,10–12]. The JNKs
are activated through phosphorylation by specific MAP
kinase kinases — JNKK1 (also known as SEK1 or MKK4)
and JNKK2 (also known as SEK2 or MKK7) [10,13–15].
The JNK subgroup consists of three members — JNK1,
JNK2 and JNK3 [5,7,16] — each with multiple isoforms
generated through alternative splicing [17]. Combinatorial
use of various JNKs, JNKKs and JNKK activating MAP
kinase kinase kinases, such as MEKK1, MEKK2,
MEKK3, ASK1, TAK1 and MLK [9,18–23], can lead to
JNK activation in response to multiple stimuli and differ-
ential regulation of substrate proteins.
T-cell activation involves several steps including induc-
tion of immediate early genes, followed by induction of
interleukin-2 (IL-2), whose secretion leads to autocrine
and paracrine T-cell proliferation [24]. In T lymphocytes,
the JNKs are synergistically activated by costimulation of
the T-cell receptor (TCR) and the CD28 auxiliary recep-
tor or by a combination of pharmacological agents, phorbol
myristate acetate (PMA) and Ca2+ ionophore [25–27]. By
contrast, no synergy is observed in ERK activation. The
synergistic JNK activation response is unique to T and
B cells [26–28]. Anergic T cells have been shown to
exhibit a defective JNK activation response [29,30].
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The importance of JNK activity for T-cell activation is sug-
gested by its correlation with IL-2 induction [26,27] and the
role of the AP-1 transcription factor, which is composed of
Jun and Fos subunits. In non-stimulated T cells, the basal
levels of AP-1 proteins are low but T-cell activation results
in jun and fos gene induction [26,31]. This process partially
depends on JNK activation [26] and, consistent with the
defect in JNK activation, anergic T cells exhibit a deficient
AP-1 response [32]. In addition to pre-existing factors, such
as c-Jun, ATF2 and Elk-1, involved in c-jun and c-fos induc-
tion, the JNKs phosphorylate newly synthesized c-Jun or
JunD and enhance their ability to activate transcription [33].
Full IL-2 induction also requires stabilization of its mRNA
[34], a process in which the JNKs are also involved [35].
The role of AP-1 and the JNK pathway in T lymphocyte
development and activation has been under intense inves-
tigation [35–39]. Chimeras generated with c-Jun–/– embry-
onic stem (ES) cells exhibit poor restoration of thymocyte
number, but contain peripheral B and T cells that can be
activated efficiently [36]. Chimeras generated using
SEK1–/– ES cells give different results [37–39]. Nishina et
al. [37,38] found poor thymocyte restoration, whereas
Swat et al. [39] found normal numbers of all thymocyte
subpopulations. Swat et al. [39] also found normal activa-
tion of T cells lacking SEK1, which contrasts with the
findings of Nishina et al. [37,38]. As SEK1-deficient
embryos die at midgestation, the developmental function
of this JNK-activating kinase [13] is irreplaceable during
embryogenesis, whereas it seems to be dispensable for
T-cell differentiation and activation [39,40].
To examine the role of the JNK pathway in T-cell differen-
tiation and activation, we focused on the functions of indi-
vidual JNKs. JNK1 and JNK2 are ubiquitously expressed,
whereas JNK3 expression is restricted to the brain [41]. The
predominant isoform of JNK2 exhibits higher affinity to c-
Jun than the predominant JNK1 isoform [7]. We generated
JNK2-null mice, which were viable and fertile and had no
overt developmental abnormalities. Although the differenti-
ation of T and B lymphocytes was not altered, T-cell activa-
tion was impaired. Activated peripheral T cells produced
less IL-2, IL-4 and interferon-γ (IFN-γ), as a consequence
of reduced JNK activity. Moreover, activation-induced thy-
mocyte death was affected, as double-positive (DP)
CD4+CD8+ thymocytes lacking JNK2 were relatively resis-
tant to apoptosis induced by injecting antibodies to the
CD3 component of the TCR complex. In contrast, B cells
were efficiently activated in the absence of JNK2.
Results
Generation of mice with a disrupted JNK2 gene
The JNK2 gene was inactivated by homologous recombi-
nation using a targeting construct that lacked parts of the
kinase domain (Figure 1a). Heterozygous mice appeared
phenotypically normal and were intercrossed to produce
mice homozygous for the mutation (Figure 1b). Homozy-
gous mutants were viable, fertile and exhibited no macro-
scopic abnormalities at birth. The expected 4.5 kb JNK2
transcript was present in wild-type but not in JNK2–/–
mice (Figure 1c). No truncated JNK2 mRNA could be
detected in any tissue from JNK2–/– mice and there was no
compensatory increase in the levels of either JNK1 or
JNK3 mRNA (Figure 1c).
JNK isoforms migrating at 46 and 55 kDa are generated by
alternative splicing of each primary JNK transcript [17].
Wild-type splenocytes and thymocytes express high levels
of the 55 kDa JNK2 isoform but extremely low levels of
the 46 kDa isoform (Figure 1d). Primary embryonic
fibroblasts express lower levels of the 55 kDa JNK2
isoform and barely detectable levels of the 46 kDa isoform
(Figure 1d). Cells derived from JNK2–/– mice, however,
did not express either of the JNK2 isoforms (Figure 1d).
The major JNK1 isoform is the 46 kDa one although
fibroblasts express more of the 55 kDa isoform than do
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Figure 1
Targeted mutation of the murine JNK2 gene in ES cells. (a) Structure of
the genomic DNA encoding a portion of the protein kinase domain of
JNK2 (top). The targeting vector (middle) replaced parts of exons 1 and
2 (E1, E2) with a β-galactosidase (lacZ) gene fused in frame with E1 and
a neo cassette driven by the Rous sarcoma virus (RSV) promoter. DT-A,
diptheria toxin A gene. The structure of the targeted allele following
homologous recombination is depicted below. (b) Genotype analysis by
Southern blotting of DNA isolated from offspring of heterozygous
intercrosses. The probe indicated in (a) was used. (c) JNK1, JNK2, JNK3
and GAPDH mRNA expression. (d) Western blot analysis of JNK protein
expression in primary embryonic fibroblasts, splenocytes and thymocytes
from wild-type and homozygous mutant cells. The positions of the long
(L) and short (S) isoforms of the JNK proteins are indicated.
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splenocytes and thymocytes. Both JNK1 isoforms were
present at similar levels in wild-type and JNK2–/– cells
(Figure 1d). No truncated JNK2 polypeptide reactive with
our antiserum was detected. These results indicate that
the targeted mutation of the JNK2 gene results in com-
plete absence of a functional gene product.
JNK2 is not required for development of primary B or T
lymphocytes
JNK signaling has been implicated in development of both
B and T lymphocytes [37,38]. Development of B and T
cells was not impaired in mice lacking JNK2. The frequen-
cies of B220+CD43– and B220+IgM+ mature B cells in bone
marrow and spleen of JNK2–/– mice were indistinguishable
from those of wild-type mice (Figure 2a,b). Using CD4 and
CD8 as markers for differentiation stages of thymocytes,
we found that JNK2–/– mice had normal numbers and pro-
portions of CD4–CD8–, CD4+CD8+, CD4+CD8– and
CD4–CD8+ thymocytes (Figures 2d,3). Finally, JNK2–/–
splenic T-cell populations were phenotypically similar to
those of wild-type mice, as assessed by staining with anti-
bodies to CD4, CD8, CD3, heat-stable antigen (HSA),
TCRαβ, TCRγδ, Thy 1.2, CD44 and CD25 (Figure 2c;
data not shown). The number of spleen cells in JNK2–/–
mice was normal (Figure 2d). Therefore JNK2 is not
required for normal development of B or T lymphocytes.
JNK2–/– thymocytes are resistant to cell death induced by
anti-CD3 antibody in vivo
To determine whether JNK2 is essential for induction of
cell death in thymocytes, we injected the potent pan-T-
cell activator, anti-CD3 antibody, intraperitoneally into
wild-type and JNK2–/– mice and analysed the mice for
depletion of DP CD4+CD8+ thymocytes. Wild-type mice
injected with anti-CD3 antibody exhibited nearly com-
plete depletion of the DP cell compartment 48 hours post-
injection (Figure 3a), and the thymi were dramatically
reduced in size (0.1–0.05 × that of untreated mice; data
not shown). In contrast, thymi of JNK2–/– mice injected
with anti-CD3 antibody were about 0.4 × the size of thymi
from untreated mutant mice 48 hours post-injection (data
not shown) and the DP compartment was only partially
depleted (Figure 3a). Time-course analysis of apoptosis
revealed that, while wild-type thymocytes began to die by
24 hours post-injection (only 52% of all cells were DP thy-
mocytes), the JNK2–/– DP thymocyte population was unal-
tered (85% of total) at this point (Figure 3a). Thus, the
absence of JNK2 confers resistance to DP thymocytes
against cell death induced by administration of antibody
to the CD3 component of the TCR in vivo.
Induction of JNK activity, that is, JNK-mediated c-Jun phos-
phorylation, was examined next (Figure 3b). JNK activity in
wild-type thymic extracts was detected 24 hours after anti-
CD3 antibody injection, that is, at the time point when cell
death was first observed. Hence, JNK activation coincides
with thymocyte cell death induced by anti-CD3 antibody. As
expected, injection of anti-CD3 antibody did not increase
JNK activity in JNK2–/– thymic extracts (Figure 3b).
Susceptibility of JNK2–/– thymocytes to cell death induced
by anti-CD3 antibody and other apoptotic stimuli in vitro
To determine whether the resistance of JNK2–/– DP thy-
mocytes to apoptosis induced by injection of anti-CD3
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Figure 2
JNK2 is not required for normal development of B and T lymphocytes.
Flow cytometric analysis of cells from (a) bone marrow and 
(b,c) spleen of wild-type and JNK2–/– 12-week-old mice. The results
shown are representative of six mice per group. (d) The numbers of
thymic and splenic cells from 12-week-old mice are shown, each point
corresponding to an individual mouse.
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antibody is a cell-autonomous defect, we compared the
susceptibility of JNK2–/– and wild-type thymocytes to cell
death induced by direct incubation with anti-CD3 anti-
body in the presence of an antibody that activates the
CD28 auxiliary receptor. Although JNK2–/– thymocytes
directly incubated with a range of anti-CD3 antibody con-
centrations were markedly resistant to apoptosis
(Figure 4a,b), the difference in survival of cells of the two
genotypes was not as dramatic as after administration of
anti-CD3 antibody in vivo (Figure 3). JNK2–/– thymocytes
were, however, consistently more resistant than their wild-
type counterparts to incubation with a low dose (10 µg/ml)
of anti-CD3 antibody (97% versus 77%, and 72% versus
44% viability at 24 and 48 hours, respectively; Figure 4a,b).
At a higher dose of anti-CD3 antibody  (100 µg/ml), 96% of
JNK2–/– thymocytes were viable at 24 hours compared with
70% of wild-type thymocytes (Figure 4a,b). After 48 hours,
JNK2–/– thymocytes were still more resistant than wild-
type thymocytes (Figure 4b). Thus, JNK2 appears to be
necessary for apoptotic responses induced by anti-CD3
antibody in vivo and in vitro. 
We also induced thymocyte death by incubation with
either an agonistic anti-Fas antibody or the synthetic glu-
cocorticoid dexamethasone, or by exposure to ultraviolet-
C (UVC) radiation. In these cases, JNK2–/– thymocytes
were not significantly more resistant to apoptosis than
their wild-type counterparts (Figure 4c–g). No difference
in Fas or CD3 expression was detected between JNK2–/–
and wild-type thymocytes (data not shown). Thus, the
absence of JNK2 did not confer marked resistance to
apoptosis mediated by anti-Fas antibody, dexamethasone
or UVC radiation, suggesting that JNK2 is specifically
involved in thymocyte apoptosis induced by anti-CD3
antibody. In addition, the marked resistance of JNK2–/–
thymocytes to cell death induced by in vivo delivery of
anti-CD3 antibody might not be fully cell autonomous
and could well depend on factors produced outside the
DP thymocyte compartment.
Activation and proliferation, but not cell death, is impaired
in JNK2–/– peripheral T lymphocytes
As production of cytokines by peripheral T cells that sub-
sequently induce expression of cell-death mediators has
been suggested as a mechanism for DP cell killing
induced by anti-CD3 antibody in vivo [42], we examined
the in vitro activation of JNK2–/– peripheral T cells by anti-
bodies to CD3 and CD28. Purified splenic T cells were
cultured on plates coated with anti-CD3 antibody, in the
absence or presence of anti-CD28 antibody. Although
both wild-type and JNK2–/– T cells proliferated in
response to this treatment, T cells lacking JNK2 consis-
tently exhibited markedly reduced proliferation rates,
especially at lower/limiting concentrations of activating
stimuli (Figure 5a–c). Wild-type T cells proliferated vigor-
ously in response to plate-bound anti-CD3 antibody
(10 µg/ml), whereas JNK2–/– T cells showed significantly
reduced proliferation rates (Figure 5a). When T-cell prolif-
eration was analyzed at lower concentrations of anti-CD3
antibody (1 µg/ml) in the presence of various anti-CD28
antibody concentrations, wild-type T cells exhibited
enhanced proliferation rates in a dose-dependent manner,
in contrast to JNK2–/– T cells which failed to respond to
the costimulatory antibody (Figure 5b). The difference
between T cells of the two genotypes became less signifi-
cant at high doses of anti-CD3 and anti-CD28 antibodies,
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Figure 3
Lack of JNK2 results in increased resistance
of immature thymocytes to cell death induced
by anti-CD3 antibody. (a) Wild-type and
JNK2–/– mice were injected with phosphate-
buffered saline (PBS) or anti-CD3 antibody,
and thymi were removed for flow cytometric
analysis after the indicated time periods. The
results are representative of nine wild-type
and eight JNK2–/– mice per group. (b) JNK
activity in thymocytes from mice injected with
anti-CD3 antibody was assayed using a
glutathione-S-transferase fusion protein
coupled to amino acids 1–79 of c-Jun
(GST–c-Jun) as a substrate.
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Time (h):
however (Figure 5c). These data indicate that the prolifer-
ation defect depends on the level of costimulation. 
Analysis of cytokine production after 36 hours in culture
revealed that wild-type T cells produced significant
amounts of IL-2, IL-4 and IFN-γ, whereas JNK2–/–
T cells produced barely detectable levels of these
cytokines (Figure 5d–l). As the cytokines produced by
activated T cells are used in a paracrine/autocrine manner
for further proliferation, we also analyzed cytokine pro-
duction after 24 hours. At this point, JNK2–/– T cells pro-
duced significant amounts of IL-2, which nevertheless
were lower than those produced by wild-type cells, espe-
cially at low levels of costimulation (Figure 5m). The
impaired production of IL-2, IL-4 and IFN-γ by JNK2–/–
T cells correlates with the inefficient activation and prolif-
eration of these cells and most likely is the cause for the
proliferation defect, as treatment with anti-CD3 antibody
resulted in equal levels of IL-2 receptor α chain expres-
sion in wild-type and JNK2–/– T cells (data not shown).
Indeed, when purified T cells from wild-type and JNK2–/–
mice were stimulated with low doses of anti-CD3 and
anti-CD28 antibodies in the presence of exogenous IL-2,
no differences in their proliferation capacity were
detectable (Figure 5n).
Inefficient proliferation of JNK2–/– mature T cells was a
direct consequence of impaired activation as we have
found that JNK2–/– peripheral T cells are not more sus-
ceptible to apoptosis induced by anti-CD3 antibody
(Figure 5o; data not shown). Collectively, these findings
indicate that the lack of JNK2 results in inefficient activa-
tion of peripheral T cells in response to anti-CD3-anti-
body injection, which probably results in insufficient
signals being relayed to the thymus to induce the death
of DP cells.
We examined whether DNA-binding activity of the tran-
scription factor AP-1 is affected in JNK2-deficient T lym-
phocytes. Nuclear extracts from wild-type and JNK2–/–
peripheral T cells activated with anti-CD3 antibody
exhibited similar levels of AP-1-binding activity
(Figure 6a). Furthermore, addition of a pan-Jun antibody
resulted in further retardation of the complex. Moreover,
c-Jun, JunB and JunD were all found at similar levels in
AP-1 complexes from nuclear extracts of both wild-type
and JNK2–/– T cells (data not shown). 
We next investigated whether the total amount of JNK
activity is reduced in JNK2–/– T cells. Splenic T cells were
stimulated for various times with either anti-CD3 anti-
body alone or in combination with anti-CD28 antibody or
with PMA and ionomycin. Induction of JNK activity was
observed in both wild-type and JNK2–/– T cells, although
the activity was lower in the latter (Figure 6b). Western
blotting indicated that JNK1 expression was not upregu-
lated in JNK2–/– T cells (Figure 6b).
Lack of JNK2 does not affect B-cell activation
CD40 signaling in B cells results in JNK activation [43].
However, JNK2–/– B cells proliferated normally in
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Figure 4
Susceptibility of JNK2-deficient thymocytes to cell death caused by
direct incubation with anti-CD3 antibody, and other apoptotic stimuli in
vitro. (a,b) Thymocytes from wild-type (open symbols) and JNK2–/–
(filled symbols) mice were cultured on 24-well plates coated with anti-
CD3ε antibody for (a) 24 h or (b) the indicated periods in the presence
of soluble anti-CD28 antibody, and their viability determined. (c,d) Cell
death was induced by 40 and 80 J/m2 of UVC radiation, and cell
viability was determined after (c) 24 h or (d) 24 h and 48 h post
80 J/m2 UVC irradiation. (e–g) Thymocyte viability was determined
(e) after treatment with various concentrations of dexamethasone for
24 h, or (f) with 10–7 M dexamethasone for various time periods, or
(g) after 24 h incubation with various concentrations of anti-Fas
antibody. The results are representative of three independent
experiments, each using three pairs of mice.
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response to lipopolysaccharide (LPS), IL-4, anti-CD40
antibody or IL-4 plus anti-CD40 antibody (Figure 7a).
Moreover, JNK2–/– B cells upregulated CD23 upon CD40
stimulation (data not shown). JNK activation is also impli-
cated in B-cell differentiation within germinal centers
[44]. We thus examined germinal center formation follow-
ing immunization with dinitrophenyl ovalbumin
(DNP–OA) in JNK2–/– mice and found normal formation
of germinal centers (Figure 7b). Germinal center B cells of
both genotypes were positive for peanut agglutinin (PNA)
expression (Figure 7b). Thus, JNK2 deficiency does not
affect gross B-cell proliferation and differentiation.
Discussion
We generated JNK2–/– mice and found that JNK2 is not
essential for embryonic development. Mice lacking JNK1
or JNK3 also complete embryogenesis (K.S., M.K. and
E.F.W., unpublished observations; [41]), suggesting that
the loss of any individual JNK can be compensated for
during embryogenesis. Nevertheless, the results described
here indicate that JNK2 is required for efficient T-cell but
not B-cell activation, thus defining at least one cell-type-
specific function for JNK2. Moreover, within the peripheral
T-cell compartment, lack of JNK2 resulted in impaired 
T-cell activation but did not alter sensitivity to apoptotic
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Figure 5
IL-2, IL-4 and IFN-γ production by T cells
lacking JNK2 and inefficient proliferation after
stimulation with antibodies to CD3 and CD28.
(a–c) Purified T cells from spleens of 8–10-
week-old mice were cultured (a) in the
presence of the indicated concentrations of
plate-bound anti-CD3ε antibody (α-CD3), or
(b) 1 µg/ml plate-bound anti-CD3ε antibody
and the indicated concentrations of soluble
anti-CD28 antibody (α-CD28), or (c) 1 µg/ml
soluble anti-CD28 antibody and the indicated
concentrations of plate-bound anti-CD3ε
antibody. Proliferation rates were determined
at 72 h. (d–l) IL-2 (d–f), IFN-γ (g–i) or IL-4 (j–l)
production was measured by enzyme-linked
immunosorbent assay (ELISA) after 36 h
stimulation of purified T cells as described
above. (m) IL-2 production was measured
after 24 h of stimulation. (n) Proliferation rates
of purified T cells cultured in the presence of
50 U/ml IL-2 plus anti-CD3 and/or anti-CD28
antibodies. (o) Cell death of activated T cells
induced by anti-CD3 antibody. Activated
enriched splenic T cells were cultured on
plates coated with anti-CD3ε antibody and
the rates of cell death were measured as
described above. The results are
representative of three independent
experiments, each using three matched pairs
of mice.
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stimuli. In immature DP thymocytes, however, JNK2 is
required for maximal sensitivity to certain death-inducing
stimuli, such as anti-CD3 antibody, but not others, such as
anti-Fas antibody, UVC radiation and glucocorticoids.
The most dramatic difference between wild-type and
JNK2–/– mice was revealed after in vivo injection of the
pan-T-cell activator, anti-CD3 antibody — JNK2–/– DP
thymocytes were significantly resistant to induction of cell
death compared with their wild-type counterparts. JNK2–/–
thymocytes, however, were only partially resistant to death
caused by direct incubation with anti-CD3 antibody. By
contrast, in peripheral T cells, the loss of JNK2 had no
effect on activation-induced cell death and, instead,
resulted in impaired activation. It should be emphasized,
however, that this impairment is not absolute because
JNK2–/– T cells proliferated after extensive TCR stimula-
tion. Thus, JNK2 is required for T-cell activation only at
limiting levels of costimulation. While this manuscript was
under review, Yang et al. [45] reported that they found only
a marginal difference in proliferation rates and IL-2 pro-
duction between wild-type and JNK2–/– total spleen cells
(which contain accessory cells) activated with high concen-
trations of the pharmacological agents concanavalin A and
Figure 6
AP-1-binding activity and JNK activity in JNK2-deficient T cells.
(a) AP-1-binding activity was measured using nuclear extracts from
enriched splenic T cells that were untreated (–), or stimulated with anti-
CD3 antibody for the indicated times. The specific protein–DNA
complex is indicated. SC, 100× specific competitor; NSC, 100× non-
specific competitor. (b) JNK activity in enriched splenic T cells that
were untreated, or treated with anti-CD3ε antibody (α-CD3, 10 µg/ml),
anti-CD3ε (1 µg/ml) plus anti-CD28 (1 µg/ml) antibodies (α-CD3 +
α-CD28), or PMA (50 µg/ml) plus ionomycin (1 µg/ml). T cells were
stimulated for 10 min and whole cell extracts were prepared and
assayed for JNK activity. The same extracts were analyzed for their
content of JNK1 and actin by western blotting with specific antibodies.
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Figure 7
B-cell activation is not impaired in the absence of JNK2. (a) Proliferation
rates of splenic B cells in the presence of various activating stimuli.
(b) Germinal center formation. Histological sections taken from spleens
of wild-type and JNK2–/– mice after immunization with DNP–OA were
stained with fluorescein-isothiocyanate-labeled peanut agglutinin
(PNA–FITC) and phycoerythrin-conjugated anti-B220 antibody
(B220–PE). B cells localize to areas of PNA–FITC staining (yellow).
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PMA/ionomycin. It appears that the differences between
wild-type and JNK2–/– T cells become less significant with
increased intensity of the activating stimulus. Neverthe-
less, our results indicate that the defect in proliferation of
JNK2–/– T cells is due to their inability to produce suffi-
cient IL-2 in response to low-level stimulation via the TCR
and the CD28 auxiliary receptor. As both JNK1 and JNK2
are regulated in the same manner [26], it is likely that, in
the absence of JNK2, there is a partial compensation by the
different JNK1 isoforms. In support of this explanation,
activated JNK2–/– T cells exhibit a partial reduction but not
a complete loss of total JNK activity. Nevertheless, these
results indicate that JNK2 plays a major role in cytokine
induction in response to T-cell activation.
IL-2 production, the hallmark of T-cell activation, is
under control of the JNK signaling pathway [26,27,38].
The results here confirm the importance of JNK2 as an
essential component of the signaling pathway leading to
efficient IL-2 induction in normal T cells. Recently, Yang
et al. [45] reported that in vitro differentiation of purified
CD4+ cells into TH1 effector cells is defective in the
absence of JNK2. TH1 differentiation is associated with
production of both IL-2 and IFN-γ [46]. Although our
observation that there is a reduction in IFN-γ production
by JNK2–/– T cells is consistent with that of Yang et al.
[45], it should be noted that JNK2–/– T cells also produce
lower levels of IL-4, a hallmark of TH2 differentiation
[46]. Thus, it is unlikely that JNK2 (or JNK1 for that
matter) is specifically involved in production of effector
T cells rather than being generally required for efficient
activation of all T-cell types. Most likely, JNK activation
is required for optimal production of many cytokines,
whose genes are responsive to AP-1.
How does inefficient peripheral T-cell activation result in
increased resistance of DP thymocytes to administration of
anti-CD3 antibody in vivo? It was recently shown that acti-
vation of the peripheral T-cell compartment causes selective
depletion of DP thymocytes [42]. Presumably, activation of
T cells results in direct or indirect (for example, via
macrophages) production of cytokines that kill DP thymo-
cytes. As JNK2–/– peripheral T cells produce less IL-2, IL-4
and IFN-γ, it is likely that this activation defect is largely
responsible for the marked decrease in killing of DP thymo-
cytes following administration of anti-CD3 antibody in vivo.
Interestingly, thymocytes from mice that are deficient in the
α and β subunits of the IL-2 receptor or IL-2 exhibit
decreased sensitivity to cell death induced by incubation
with anti-CD3 antibody in vitro. [47–49]. As JNK2–/– thymo-
cytes are also partially resistant to activation-induced cell
death caused by direct incubation with anti-CD3 antibody,
it is possible that their marked resistance to administration
of anti-CD3 antibody in vivo is a combination of this cell-
autonomous defect and the decreased production of cell-
death-inducing  cytokines by JNK2–/– cells in the periphery.
The involvement of the JNK signaling pathway in apopto-
sis seems to depend on the cell type and the death-induc-
ing stimulus. In DP thymocytes, the loss of JNK2 does not
significantly alter their ability to undergo apoptosis
induced by anti-Fas antibody, UVC and glucocorticoid in
vitro, although it confers resistance to apoptosis caused by
direct treatment with anti-CD3 antibody. The latter
effect, however, is unique to thymocytes, as peripheral
JNK2–/– T cells are not more resistant to cell death
induced by anti-CD3 antibody than their wild-type coun-
terparts. Also, wild-type and JNK2–/– B cells are equally
sensitive to apoptosis caused by IgM crosslinking (data
not shown). Thus, if JNK is involved in apoptosis of
mature (B and T) lymphocytes, the loss of JNK2 must
have been efficiently compensated for by JNK1.
The importance of the JNKK (SEK)–JNK–c-Jun/ATF2
pathway in lymphocyte development and activation is
becoming increasingly clear with the generation of indi-
vidual knockout mice. Studies with mutant SEK1
(JNKK1) lymphocytes indicate that this JNK-activating
kinase is not required for lymphocyte development but is
essential for maintenance of a normal peripheral compart-
ment [39]. Our data further suggest that JNK2 is not
required for lymphocyte development but is essential for
efficient T-lymphocyte activation. Moreover, although
T lymphocytes lacking c-Jun do not show an activation
defect [36], JNK2 is required for efficient T-cell activa-
tion. The precise definition of the JNK substrates that are
involved in T-lymphocyte development and activation
should emerge with the continuing analysis of individual
and compound knockout mouse strains.
Conclusions
The results presented here provide strong genetic evi-
dence that the MAP kinase JNK2 is required in a cell-type-
specific and signal-specific manner for activation of mature
T cells and apoptosis of immature DP thymocytes. The
loss of JNK2 does not affect the apoptotic response of
mature T cells to anti-CD3 antibody, but renders immature
DP thymocytes resistant to this cell-death-inducing stimu-
lus. The resistance of DP thymocytes lacking JNK2 to anti-
CD3 antibody treatment is largely dependent on peripheral
T-cell activation, however. Moreover, the requirement for
JNK2 of immature DP thymocytes to undergo apoptosis is
stimulus-dependent; JNK2 is required for the apoptotic
response to anti-CD3 antibody, but not to Fas ligation,
UVC radiation or glucocorticoid treatment.
Materials and methods
Generation of JNK2–/– mice by gene targeting
The JNK2 gene-targeting construct was made by subcloning a
PvuI–XbaI fragment containing sequences encoding the first 32 amino
acids of exon 1 in frame with the lacZ gene in the pGNA vector. The
diptheria toxin A gene was used as a negative selection marker together
with the MCI promoter in pGNA containing the JNK2 sequences. D3
and R1 ES cells were electroporated with PmeI-linearized JNK2 
targeting construct and screened for homologous recombination events.
SacI-digested ES cell DNA was probed with a 2 kb XbaI–SacI fragment
(Figure 1a), which detects an 11 kb fragment from the wild-type allele
and an 8 kb fragment from the targeted allele. Two independent tar-
geted ES cell clones were injected into blastocysts of C57BL/6 mice.
Heterozygous mice were interbred to obtain JNK2–/– mice, which were
genotyped by PCR using the following primers: 5′-
TCCAGTACAGCGCGGCTGAA-3′ and 5′-GCAGCAGCCCTCAG
GATCCT-3′, which detect the mutant allele, and 5′-TCTGACGTC-
CTGGGCTGGAC-3′ and 5′-GCAGCAGCCCTCAGGATCCT-3′,
which detect the wild-type allele. Northern analysis was performed
according to standard protocols using polyA+ RNA isolated from brain
of wild-type, JNK2+/– and JNK2–/– mice, and hybridized with cDNA frag-
ments specific for mouse JNK1, JNK2, JNK3 and GAPDH.
Western blot analysis and JNK assay
Western blots [7] using 100 µg whole cell extracts from primary
embryonic fibroblasts, thymocytes and splenic T cells were probed
with anti-JNK1(333.8) or anti-JNK(666.8) antibodies (Pharmingen).
Kinase assays were performed using 60 µg whole cell extracts and
GST–c-Jun(1–79) as a substrate [7], and quantified by Phosphorim-
ager analysis (Molecular Dynamics). Relative JNK activity is repre-
sented by pixel values obtained by quantification of the intensity of the
signal. Parallel samples were analyzed for protein expression by
immunoblotting with anti-JNK1 and anti-actin antibodies (Sigma).
Flow cytometric analysis
Single-cell suspensions of thymus, spleen and bone marrow were pre-
pared, stained by standard procedures and analyzed on a FACScan
flow cytometer (Becton Dickinson) using CellQuest software.
Proliferation assays and ELISA
T cells from spleens of wild-type, JNK2+/– and JNK2–/– mice were puri-
fied by isolating the CD4+ and CD8+ populations by FACS. Purified
cells were plated in 96-well plates precoated with anti-CD3ε antibody
for 2 h at 37°C in the absence or presence of soluble anti-CD28 anti-
body. After 60 h, cultures were pulsed for 10–12 h with 1 µCi
[3H]thymidine per well and cells were subsequently harvested and ana-
lyzed using standard procedures. T lymphocytes stimulated with anti-
CD3ε antibody for 24 and 36 h were harvested, and the supernatants
used for measurement of IL-2 , IFN-γ and IL-4 levels by ELISA (R&D
Systems); 50 U/ml  IL-2 was added to cells for proliferation assays per-
formed in the presence of exogenous IL-2. JNK2+/– cells gave similar
results to wild-type cells and there was no effect of gene dosage
resulting from less JNK2 mRNA transcript. B-cell proliferation was ana-
lyzed by stimulation of total spleen cells with IL-4 (50 U/ml), soluble
anti-CD40 antibody (1 µg/ml), IL-4 plus anti-CD40 antibody or LPS
(10 µg/ml). The magnitude of stimulated [3H]thymidine or bromo-
deoxyuridine (BrdU) incorporation over background values are indi-
cated as fold-stimulation. All experiments were performed in triplicate.
In vivo thymocyte death assay
Wild-type and JNK2–/– mice (12 weeks old) were injected with either
PBS or 50 µg purified anti-CD3ε antibody intraperitoneally. After
various time periods, mice were sacrificed and thymocytes subjected
to flow cytometric analysis after staining with appropriate antibodies.
In vitro apoptosis assays
Freshly isolated thymocytes were plated in each well of a 24-well dish
(5 × 105 cells/ml). For cell death induced by anti-CD3ε antibody, wells
were pre-coated with various concentrations of the antibody for 1 h at
37°C and thymocytes were subsequently cultured in the presence of
1 µg/ml soluble anti-CD28 antibody for the indicated periods. Apopto-
sis was also induced by addition of various concentrations of anti-Fas
antibody (clone Jo-2, Pharmingen), dexamethasone (Fluka) or by UVC
irradiation using a Stratagene crosslinker. After incubation for the indi-
cated periods at 37°C, the cells were harvested and stained with FITC-
conjugated Annexin-V (Pharmingen) and propidium iodide and analyzed
with a FACScan cytometer as described above. Thymocytes cultured in
medium alone served as controls to measure spontaneous rate of cell
death. Viability of thymocytes is expressed as percentage of viable thy-
mocytes treated with apoptotic stimuli over viability of untreated thymo-
cytes. Enriched splenic T cells were treated with 3 µg/ml
concanavalin-A for 48 h, washed in 10 mg/ml α-methylmannosidase
and cultured for additional 48 h in the presence of 50 U/ml IL-2. The
cells were then washed and plated (1 × 106 cells/well) on 24-well
plates coated with anti-CD3ε antibody (20 µg/ml), and cell death was
measured at the indicated times. Individual treatments were done in
triplicate, and at least three experiments were performed, each using
three matched pairs of wild-type and JNK2–/– mice.
Nuclear extracts and electrophoretic mobility shift assay
Nuclear extracts were prepared from 7 × 106 enriched splenic T cells
as described [38]. The double-stranded oligonucleotide used in the
mobility shift assay was from the human osteocalcin AP-1 site (5′-
GGGTGACTCACCGGGTGAA-3′). For supershift experiments, 2 µg
anti-Jun antibody (Santa Cruz, SC-44) was added to the reactions.
Germinal center formation and immunohistochemistry
Mice were injected intraperitonially with 100 µg DNP–OA in complete
Freund’s adjuvent on day 0 and boosted on day 21; 10 days after sec-
ondary immunization, spleens were snap frozen and processed for
cryosections. Cryosections were stained with FITC-conjugated peanut
agglutinin (Vector) and PE-conjugated anti-B220 antibody (Pharmingen).
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